CNSP CNS PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, CNS PHARMACEUTICALS INC reported revenue of n/a, net income of −$2.59M and diluted EPS of −$0.38; for the fiscal year ended December 2025 revenue was n/a.
CNSP annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$16.0M, net income −$16.0K (margin n/a), EPS −$35.75
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$14.9M, net income −$14.9K (margin n/a), EPS −$466.89
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$18.9M, net income −$18.9K (margin n/a), EPS −$12509.11
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$15.3M, net income −$15.3M (margin n/a), EPS −$11.22
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$14.5M, net income −$14.5M (margin n/a), EPS −$16.50
CNSP quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$2.59M, EPS −$0.38
- Quarter ended Mar 31, 2026: revenue n/a, net income −$4.94M, EPS −$7.30
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $9.88M, EPS −$4.64
- Quarter ended Sep 30, 2025: revenue n/a, net income −$3.22M, EPS −$5.76
- Quarter ended Jun 30, 2025: revenue n/a, net income −$2.38M, EPS −$6.42
- Quarter ended Mar 31, 2025: revenue n/a, net income −$4.30M, EPS −$18.93
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income $11.7M, EPS $4755.99
- Quarter ended Sep 30, 2024: revenue n/a, net income −$5.61M, EPS −$153.20
- Quarter ended Jun 30, 2024: revenue n/a, net income −$2.53M, EPS −$4049.20
- Quarter ended Mar 31, 2024: revenue n/a, net income −$3.54M, EPS −$1020.48
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income $13.5M, EPS −$12400.52
- Quarter ended Sep 30, 2023: revenue n/a, net income −$4.52M, EPS −$54.14
- Quarter ended Jun 30, 2023: revenue n/a, net income −$4.02M, EPS −$51.86
- Quarter ended Mar 31, 2023: revenue n/a, net income −$4.93M, EPS −$2.59
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$5.14M, EPS −$3.55
- Quarter ended Sep 30, 2022: revenue n/a, net income −$3.42M, EPS −$2.56
- Quarter ended Jun 30, 2022: revenue n/a, net income −$3.57M, EPS −$2.67
- Quarter ended Mar 31, 2022: revenue n/a, net income −$3.15M, EPS −$2.44
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$3.25M, EPS −$16.06
- Quarter ended Sep 30, 2021: revenue n/a, net income −$3.81M, EPS −$0.14
CNSP cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$13.8M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$17.1M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$14.1M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$10.6M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$13.5M, share buybacks n/a
CNSP balance sheet
- Jun 30, 2026: cash $20.0M, total assets $21.9M, total liabilities $3.74M, shareholders' equity $18.2M
- Mar 31, 2026: cash $2.95M, total assets $4.65M, total liabilities $4.58M, shareholders' equity $71.0K
- Dec 31, 2025: cash $7.20M, total assets $8.62M, total liabilities $4.10M, shareholders' equity $4.52M
- Sep 30, 2025: cash $9.86M, total assets $11.9M, total liabilities $1.96M, shareholders' equity $9.91M
- Jun 30, 2025: cash $12.1M, total assets $14.5M, total liabilities $1.38M, shareholders' equity $13.1M
- Mar 31, 2025: cash $13.0M, total assets $13.7M, total liabilities $2.78M, shareholders' equity $11.0M
- Dec 31, 2024: cash $6.46M, total assets $8.70M, total liabilities $2.52M, shareholders' equity $6.18M
- Sep 30, 2024: cash $6.97M, total assets $7.41M, total liabilities $4.06M, shareholders' equity $3.35M
Is CNSP profitable?
No. CNS PHARMACEUTICALS INC lost $865K over the last four quarters.
What is CNSP's EPS?
Diluted earnings per share over the last four quarters were −$18.08; −$0.38 in the latest quarter.